Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype
- 29 January 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (3), 836-844
- https://doi.org/10.1158/0008-5472.can-08-2590
Abstract
Tumor dormancy has important implications for early detection and treatment of cancer. Lack of experimental models and limited clinical accessibility constitute major obstacles to the molecular characterization of dormant tumors. We have developed models in which human tumors remain dormant for a prolonged period of time (>120 days) until they switch to rapid growth and become strongly angiogenic. These angiogenic tumors retain their ability to grow fast once injected in new mice. We hypothesized that dormant tumors undergo a stable genetic reprogramming during their switch to the fast-growing phenotype. Genome-wide transcriptional analysis was done to dissect the molecular mechanisms underlying the switch of dormant breast carcinoma, glioblastoma, osteosarcoma, and liposarcoma tumors. A consensus expression signature distinguishing all four dormant versus switched fast-growing tumors was generated. In alignment with our phenotypic observation, the angiogenesis process was the most significantly affected functional gene category. The switch of dormant tumors was associated with down-regulation of angiogenesis inhibitor thrombospondin and decreased sensitivity of angiogenic tumors to angiostatin. The conversion of dormant tumors to exponentially growing tumors was also correlated with regulation and activation of pathways not hitherto linked to tumor dormancy process, such as endothelial cell–specific molecule-1, 5′-ecto-nucleotidase, tissue inhibitor of metalloproteinase-3, epidermal growth factor receptor, insulin-like growth factor receptor, and phosphatidylinositol 3-kinase signaling. Further, novel dormancy-specific biomarkers such as H2BK and Eph receptor A5 (EphA5) were discovered. EphA5 plasma levels in mice and mRNA levels in tumor specimens of glioma patients correlated with diseases stage. These data will be instrumental in identifying novel early cancer biomarkers and could provide a rationale for development of dormancy-promoting tumor therapy strategies. [Cancer Res 2009;69(3):836–44]Keywords
This publication has 32 references indexed in Scilit:
- Models, mechanisms and clinical evidence for cancer dormancyNature Reviews Cancer, 2007
- Transcriptional network governing the angiogenic switch in human pancreatic cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- p130‐Angiomotin associates to actin and controls endothelial cell shapeThe FEBS Journal, 2006
- Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesisThe FASEB Journal, 2006
- A Model of Human Tumor Dormancy: An Angiogenic Switch From the Nonangiogenic PhenotypeJNCI Journal of the National Cancer Institute, 2006
- Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell MotilityPublished by Elsevier BV ,2005
- Cancer without diseaseNature, 2004
- AIDS‐related Kaposi's sarcoma cells rapidly internalize endostatin, which co‐localizes to tropomysin microfilaments and inhibits cytokine‐mediated migration and invasionJournal of Cellular Biochemistry, 2003
- Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancyThe FASEB Journal, 2002
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995